Studie fáze 2 s analumabem (VAY736) u pacientů s primární imunitní trombocytopenií (ITP), kteří byli dříve léčeni alespoň dvěma řadami terapií
Studie fáze 2 k vyhodnocení účinnosti a bezpečnosti ianalumabu (VAY736) u pacientů s primární imunitní trombocytopenií (ITP) dříve léčených alespoň kortikosteroidem a agonistou trombopoetinového receptoru (TPO-RA)
The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count <30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.
The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Rozšířený přístup
Rozšířený přístup
Dostupný
- Dostupné: Pro tuto zkoumanou léčbu je v současné době k dispozici rozšířený přístup a pacienti, kteří nejsou účastníky klinické studie, mohou získat přístup k léku, biologickému nebo lékařskému zařízení. právě se studuje.
- Již není k dispozici: Rozšířený přístup byl pro tento zásah k dispozici dříve, ale v současnosti není dostupný a nebude dostupný ani v budoucnu.
- Dočasně nedostupné: Rozšířený přístup není v současné době pro tento zásah k dispozici, ale očekává se, že bude dostupný v budoucnu.
- Schváleno pro marketing: Zásah byla schválena americkým Úřadem pro kontrolu potravin a léčiv pro použití veřejností.
Kontakty a umístění
Studijní místa
-
-
-
CABA, Argentina, C1181ACH
- Novartis Investigative Site
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Austrálie, 2605
- Novartis Investigative Site
-
-
Victoria
-
Melbourne, Victoria, Austrálie, 3004
- Novartis Investigative Site
-
-
-
-
-
Toulouse, Francie, 31059
- Novartis Investigative Site
-
-
-
-
TO
-
Torino, TO, Itálie, 10126
- Novartis Investigative Site
-
-
-
-
-
Seoul, Jižní Korea, 06591
- Novartis Investigative Site
-
-
-
-
-
Johor Bahru, Malajsie, 80100
- Novartis Investigative Site
-
-
-
-
-
Giessen, Německo, 35392
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Německo, 01307
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Německo, 07740
- Novartis Investigative Site
-
-
-
-
-
Katowice, Polsko, 40-519
- Novartis Investigative Site
-
-
-
-
-
Glasgow, Spojené království, G31 2ER
- Novartis Investigative Site
-
London, Spojené království, W12 0HS
- Novartis Investigative Site
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Spojené státy, 02215
- Beth Israel Deaconess Med Center
-
-
-
-
-
Izmir, Turecko (Türkiye), 35100
- Novartis Investigative Site
-
Kocaeli, Turecko (Türkiye), 41380
- Novartis Investigative Site
-
-
Efeler
-
Aydin, Efeler, Turecko (Türkiye), 09100
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turecko (Türkiye), 34098
- Novartis Investigative Site
-
-
Merkez
-
Edirne, Merkez, Turecko (Türkiye), 22030
- Novartis Investigative Site
-
-
-
-
-
Beijing, Čína, 100730
- Novartis Investigative Site
-
Jinan, Čína, 250012
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Čína, 430022
- Novartis Investigative Site
-
-
-
-
Catalonia
-
Barcelona, Catalonia, Španělsko, 08003
- Novartis Investigative Site
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Signed informed consent obtained prior to participation in the study.
-
Male or female participants aged 18 years and older on the day of signing informed consent.
-
Confirmed diagnosis of primary ITP.
- Prior treatment with at least a corticosteroid (±IVIG) and a TPO-RA:
- Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
- Prior response to IVIG/anti-D or a corticosteroid (platelet count ≥50 G/L) that was not maintained.
-
At last ITP treatment, loss of response, insufficient response, no response or intolerance.
-
Platelet count <30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value <30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.
Key exclusion criteria:
-
Diagnosis of secondary thrombocytopenia.
-
Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.
-
Participants with the following conditions at screening:
- Neutrophils <1000/mm3.
- Immunoglobulin G (IgG) <5 g/L
-
Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.
-
Immunosuppressant drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.
-
Prior splenectomy.
Other protocol-defined inclusion/exclusion criteria may apply.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Single-arm
All eligible participants will receive ianalumab at the same dose. |
Intravenous infusion, prepared from concentrate solution
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Confirmed response
Časové okno: Between Week 1 Day 1 and Week 25 Day 1
|
Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:
|
Between Week 1 Day 1 and Week 25 Day 1
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Time to confirmed response
Časové okno: From Week 1 Day 1 to Week 25 Day 1
|
Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint. |
From Week 1 Day 1 to Week 25 Day 1
|
|
Duration of confirmed response
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:
|
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Complete Response rate at each timepoint
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Response rate at each timepoint
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Stable response at 6 months
Časové okno: At 6 months
|
Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment. |
At 6 months
|
|
Stable response at 1 year
Časové okno: At 1 year
|
Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment. |
At 1 year
|
|
Bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Number of participants who received rescue treatment
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Number of participants who required rescue treatment |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Percentage of participants who received rescue treatment
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Percentage of participants who required rescue treatment |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in the frequency of CD19+ B-cell counts
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline frequency of CD19+ B-cell counts compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in the absolute number of CD19+ B-cell counts
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from baseline in immunoglobulins
Časové okno: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline |
From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Incidence of anti-ianalumab antibodies in serum (ADA assay) over time
Časové okno: Up to 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Up to 20 weeks after last dose of ianalumab
|
|
Titer of anti-ianalumab antibodies in serum (ADA assay) over time
Časové okno: Up to 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Up to 20 weeks after last dose of ianalumab
|
|
Ianalumab serum concentrations over time
Časové okno: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK: AUC concentrations over time
Časové okno: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK parameters: Cmax
Časové okno: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Ianalumab serum PK parameters: Tmax
Časové okno: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)
|
|
Confirmed response (CR) in the second course
Časové okno: Second course Week 1 Day1 to second course Week 25 Day1
|
Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of:
|
Second course Week 1 Day1 to second course Week 25 Day1
|
|
Time to confirmed response in the second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
two (or more) platelet assessments meeting the criteria of a confirmed response. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Duration of confirmed response in the second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events:
|
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Response in the second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Complete Response in the second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal. |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Number of Participants who received rescue treatment after second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Number of participants who required rescue treatment |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Percentage of participants who received rescue treatment after receiving second course
Časové okno: Second course Week 1 Day 1 to second course Week 25 Day 1
|
Percentage of participants who required rescue treatment |
Second course Week 1 Day 1 to second course Week 25 Day 1
|
|
Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course
Časové okno: Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
|
Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab |
Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab
|
|
Change from start of second course in immunoglobulins
Časové okno: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from start of second course in the absolute number of CD19+ B-cell counts
Časové okno: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Change from start of second course to end of study in the absolute number of CD19+ B-cell counts
Časové okno: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Post-baseline absolute number of CD19+ B-cell counts compared to baseline |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL
Časové okno: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL |
From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)
|
|
Ianalumab serum concentrations over time in the second course
Časové okno: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course
|
Ianalumab concentration in serum over time, including end of infusion and concentration at trough. |
First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Cytopenie
- Patologické procesy
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Krvácení
- Kožní projevy
- Hematologická onemocnění
- Poruchy srážení krve
- Hemoragické poruchy
- Poruchy krevních destiček
- Trombotické mikroangiopatie
- Purpura, trombocytopenická
- Purpura
- Trombocytopenie
- Patologické stavy, příznaky a symptomy
- Příznaky a symptomy
- Hemická a lymfatická onemocnění
- Purpura, trombocytopenická, idiopatická
- Ianalumab
Další identifikační čísla studie
Další identifikační čísla studie
- CVAY736Q12201
- 2022-503041-21-00 (Jiný identifikátor: EU CTIS)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .